B16alphaGal Melanoma Vaccine

A whole cell melanoma cancer vaccine with potential immunostimulating and antineoplastic activities. B16alphaGal melanoma vaccine contains three types of human melanoma cell lines that are genetically engineered to express the alpha(1,3)-galactosyl (alphaGal) epitope on cell surfaces. The agent stimulates a hyperacute rejection of whole melanoma cancer cells expressing alphaGal epitopes, initiated by opsonization by anti-alphaGal antibodies and followed by antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis. This results in the stimulation of a broader cytotoxic T-lymphocyte response (CTL) directed against tumor antigens on melanoma cells that do not express alphaGal. AlphaGal is not normally expressed in humans because alpha(1,3)-galactosyltransferase (Alpha-GT), the enzyme that catalyzes the synthesis of alphaGal epitopes on glycoproteins and glycolipids, is not naturally present in humans and other primates. (NCI Thesaurus)

YOU MAY ALSO LIKE

B(0,+)-Type Amino Acid Transporter 1

B(0,+)-type amino acid transporter 1 (487 aa, ~53 kDa) is encoded by the human SLC7A9 gene. This protein plays a role in…

B.A.D. Codes

Basic, Applied, Development codes.

B-TFIID Subunit Gene

Initiation of transcription by RNA polymerase II requires the assistance of TATA box-binding protein (TBP) and TBP-associated factors, or TAFs, in 2…

B-Symptoms

Features commonly associated with lymphoma, including fever above 38C, drenching night sweats, and weight loss of more than 10% of body mass…

B-Raf/VEGFR-2 Inhibitor RAF265

An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of…

B-Prolymphocyte

A developmental form in the B-lymphocyte series, intermediate between the B-lymphoblast and the mature B-cell.